Literature DB >> 14985374

Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer.

V Vasko1, M Saji, E Hardy, M Kruhlak, A Larin, V Savchenko, M Miyakawa, O Isozaki, H Murakami, T Tsushima, K D Burman, C De Micco, M D Ringel.   

Abstract

INTRODUCTION: Akt activation is involved in the pathogenesis of inherited thyroid cancer in Cowden's syndrome and in sporadic thyroid cancers. In cell culture, Akt regulates thyroid cell growth and survival; but recent data suggest that Akt also regulates cell motility in non-thyroid cell lines. We therefore sought to evaluate the role of Akt in thyroid cancer progression.
METHODS: We evaluated 46 thyroid cancer, 20 thyroid follicular adenoma, and adjacent normal tissues samples by immunohistochemistry for activated Akt (pAkt), Akt 1, 2, and 3, and p27 expression. Immunoblots were performed in 14 samples.
RESULTS: Akt activation was identified in 10/10 follicular cancers, 26/26 papillary cancers, and 2/10 follicular variant of papillary cancers, but in only 4/66 normal tissue samples and 2/10 typical benign follicular adenomas. Immunoactive pAkt was greatest in regions of capsular invasion; and was localised to the nucleus in follicular cancers and the cytoplasm in papillary cancers, except for invasive regions of papillary cancers where it localised to both compartments. Immunoactive Akt 1, but not Akt 2 or Akt 3, correlated with pAkt localisation, and nuclear pAkt was associated with cytoplasmic expression of p27. In vitro studies using human thyroid cancer cells demonstrated that nuclear translocation of Akt 1 and pAkt were associated with cytoplasmic p27 and cell invasion and migration. Cell migration and the localisation of Akt 1, pAkt, and p27 were inhibited by PI3 kinase, but not MEK inhibition. DISCUSSION: These data suggest an important role for nuclear activation of Akt 1 in thyroid cancer progression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14985374      PMCID: PMC1735712          DOI: 10.1136/jmg.2003.015339

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  63 in total

Review 1.  AKT plays a central role in tumorigenesis.

Authors:  J R Testa; A Bellacosa
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

2.  Carboxyl-terminal modulator protein (CTMP), a negative regulator of PKB/Akt and v-Akt at the plasma membrane.

Authors:  S M Maira; I Galetic; D P Brazil; S Kaech; E Ingley; M Thelen; B A Hemmings
Journal:  Science       Date:  2001-10-12       Impact factor: 47.728

3.  Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade.

Authors:  R M Melillo; M Santoro; S H Ong; M Billaud; A Fusco; Y R Hadari; J Schlessinger; I Lax
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

4.  Overexpression and overactivation of Akt in thyroid carcinoma.

Authors:  M D Ringel; N Hayre; J Saito; B Saunier; F Schuppert; H Burch; V Bernet; K D Burman; L D Kohn; M Saji
Journal:  Cancer Res       Date:  2001-08-15       Impact factor: 12.701

5.  Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene.

Authors:  W S Chen; P Z Xu; K Gottlob; M L Chen; K Sokol; T Shiyanova; I Roninson; W Weng; R Suzuki; K Tobe; T Kadowaki; N Hay
Journal:  Genes Dev       Date:  2001-09-01       Impact factor: 11.361

6.  Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production.

Authors:  D Kim; S Kim; H Koh; S O Yoon; A S Chung; K S Cho; J Chung
Journal:  FASEB J       Date:  2001-09       Impact factor: 5.191

7.  Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta).

Authors:  H Cho; J Mu; J K Kim; J L Thorvaldsen; Q Chu; E B Crenshaw; K H Kaestner; M S Bartolomei; G I Shulman; M J Birnbaum
Journal:  Science       Date:  2001-06-01       Impact factor: 47.728

Review 8.  Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models.

Authors:  T Kimura; A Van Keymeulen; J Golstein; A Fusco; J E Dumont; P P Roger
Journal:  Endocr Rev       Date:  2001-10       Impact factor: 19.871

Review 9.  PKB/AKT: functional insights from genetic models.

Authors:  M P Scheid; J R Woodgett
Journal:  Nat Rev Mol Cell Biol       Date:  2001-10       Impact factor: 94.444

10.  Akt1 induces extracellular matrix invasion and matrix metalloproteinase-2 activity in mouse mammary epithelial cells.

Authors:  B K Park; X Zeng; R I Glazer
Journal:  Cancer Res       Date:  2001-10-15       Impact factor: 12.701

View more
  74 in total

1.  MMP2 expression is a prognostic marker for primary melanoma patients.

Authors:  Anand Rotte; Magdalena Martinka; Gang Li
Journal:  Cell Oncol (Dordr)       Date:  2012-06-06       Impact factor: 6.730

Review 2.  Dynamic interactions between 14-3-3 proteins and phosphoproteins regulate diverse cellular processes.

Authors:  Carol Mackintosh
Journal:  Biochem J       Date:  2004-07-15       Impact factor: 3.857

3.  RNAi knockdown of PIK3CA preferentially inhibits invasion of mutant PIK3CA cells.

Authors:  Xin-Ke Zhou; Sheng-Song Tang; Gao Yi; Min Hou; Jin-Hui Chen; Bo Yang; Ji-Fang Liu; Zhi-Min He
Journal:  World J Gastroenterol       Date:  2011-08-28       Impact factor: 5.742

4.  UCH-L1 promotes invasion of breast cancer cells through activating Akt signaling pathway.

Authors:  Yanhong Luo; Jianfeng He; Chunlin Yang; Matthew Orange; Xingcong Ren; Nick Blair; Tao Tan; Jin-Ming Yang; Hua Zhu
Journal:  J Cell Biochem       Date:  2017-07-31       Impact factor: 4.429

5.  Complex regulation of the cyclin-dependent kinase inhibitor p27kip1 in thyroid cancer cells by the PI3K/AKT pathway: regulation of p27kip1 expression and localization.

Authors:  Maria Letizia Motti; Daniela Califano; Giancarlo Troncone; Carmela De Marco; Ilenia Migliaccio; Emiliano Palmieri; Luciano Pezzullo; Lucio Palombini; Alfredo Fusco; Giuseppe Viglietto
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

6.  Differentiation of trophoblast giant cells and their metabolic functions are dependent on peroxisome proliferator-activated receptor beta/delta.

Authors:  Karim Nadra; Silvia I Anghel; Elisabeth Joye; Nguan Soon Tan; Sharmila Basu-Modak; Didier Trono; Walter Wahli; Béatrice Desvergne
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

7.  Identification of a novel HRAS variant and its association with papillary thyroid carcinoma.

Authors:  Rui Dou; Lili Zhang; Tingxia Lu; Dong Liu; Fang Mei; Jian Huang; Linxue Qian
Journal:  Oncol Lett       Date:  2018-01-17       Impact factor: 2.967

8.  Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines.

Authors:  S Hoffmann; A Burchert; A Wunderlich; Y Wang; S Lingelbach; L C Hofbauer; M Rothmund; A Zielke
Journal:  Endocrine       Date:  2007-04       Impact factor: 3.633

9.  Vemurafenib may overcome TNF-related apoptosis-inducing ligand (TRAIL) resistance in anaplastic thyroid cancer cells.

Authors:  Tania Pilli; Silvia Cantara; Carlotta Marzocchi; Furio Pacini; Bellur S Prabhakar; Maria Grazia Castagna
Journal:  Endocrine       Date:  2019-08-03       Impact factor: 3.633

10.  Enhancement of cisplatin [cis-diammine dichloroplatinum (II)] cytotoxicity by O6-benzylguanine involves endoplasmic reticulum stress.

Authors:  Cara A Rabik; Melissa L Fishel; Julianne L Holleran; Kristen Kasza; Mark R Kelley; Merrill J Egorin; M Eileen Dolan
Journal:  J Pharmacol Exp Ther       Date:  2008-07-29       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.